Long-term tocilizumab therapy in patients with corticosteroid-resistant active moderate-to-severe thyroid eye disease
Authors' conclusion
Six months-TCZ therapy results in control of more than half of patients with corticosteroid-resistant TED and may provide additional improvements beyond M6. MRI might assist in the management of TED.
Study context
- Population
- Patients with corticosteroid-resistant active moderate-to-severe TED
- Participants
- 26 patients
- Outcome
- Proportion of patients achieving clinical activity score (CAS) < 3
- Follow-up
- 6 months (M6) after TCZ initiation
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
CAS < 3 · M6
Tocilizumab (TCZ)
58%
P < 0.001
Observational data: associations, not effects.
Secondary outcomes
Clinical activity score (CAS) <3 and median CAS · M3 to M18
- Proportion with CAS <3 significantly increased and median CAS declined from M3 to M18 vs baseline, and from M9 and M12 vs M6
Proptosis, diplopia, IOP and TSI detection · throughout follow-up
- Significant reduction in the proportion with proptosis, diplopia, the median IOP and TSI detection
Persistent CAS ≥3 · M12
- Patients with persistent CAS ≥3
- 2 (7.7%)
Relapse · by M18
- Patients with relapse
- 2/24 (8.3%)
MRI SIR and orbital muscle thickness · M0 to M6
- Significant decrease in SIR and orbital muscle thickness
Original publication
Long-term tocilizumab therapy in patients with corticosteroid-resistant active moderate-to-severe thyroid eye disease. Eur J Endocrinol. Published 10 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →